Form 4: Balchem Officer Backus Reports Equity Grants, Tax Withholdings

Balchem Corporation's VP & Chief Accounting Officer, William A. Backus, reported the acquisition of restricted stock and performance units, along with stock option grants and shares withheld for tax obligations.

Summary

• William A. Backus, VP & Chief Accounting Officer of Balchem Corporation, reported several equity transactions.
• Acquired 490 shares of common stock as a restricted stock grant on February 11, 2026, vesting over three years.
• Acquired 1,664 shares of common stock on February 11, 2026, from the vesting of performance stock units for the 2023-2025 period, including 29 dividend equivalent shares.
• Disposed of 865 shares of common stock on February 11, 2026, at $178.68 per share, to cover tax requirements upon the vesting of performance stock units.
• Disposed of 70 shares of common stock on February 12, 2026, at $177.49 per share, to cover withholding taxes due upon the vesting of restricted shares granted on February 12, 2025.
• Acquired 1,800 stock options on February 11, 2026, with an exercise price of $178.68 and an expiration date of February 11, 2036, vesting over three years.
• Beneficially owns 6,736 shares directly and 283 shares indirectly through a 401(k) Plan after these transactions.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting ongoing executive compensation and alignment of interests, with no unusual or concerning transactions.

Positives

• Grant of 490 restricted shares aligns management interests with shareholders.
• Vesting of 1,664 performance stock units indicates achievement of prior performance targets.
• Grant of 1,800 stock options provides future incentive for performance.

Negatives

• 865 shares were withheld at $178.68 to cover tax obligations from performance unit vesting.
• 70 shares were withheld at $177.49 to cover withholding taxes due upon vesting of restricted shares.

Future Outlook

The restricted stock grant of 490 shares will vest over a three-year period (25% on the first anniversary, 25% on the second, and 50% on the third). The 1,800 stock options granted will vest over three years (20% Year 1, 40% Year 2, and 40% Year 3), with an expiration date of February 11, 2036.

Industry Context

StockSavvy.ai notes that these transactions represent routine executive compensation, aligning the interests of William A. Backus with Balchem Corporation's long-term performance. Such equity grants are a common practice across various industries to incentivize management.

Related Party Transactions

• William A. Backus, VP & Chief Accounting Officer, received 490 restricted shares as part of his compensation.
• He also received 1,664 shares from the vesting of performance stock units for the 2023-2025 period.
• He was granted 1,800 stock options with an exercise price of $178.68.
• Shares were withheld to cover tax obligations related to these equity awards.

Stakeholder Impact

• Shareholders: The equity grants align management's financial interests with shareholder value creation. The issuance of new shares for compensation could lead to minor dilution, but this is a standard practice.
• Employees: Reflects the company's ongoing compensation strategy for its executives.

Next Steps

• Vesting of 490 restricted shares over the next three years.
• Vesting of 1,800 stock options over the next three years.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation, including equity grants and tax-related share withholdings. It does not present new information that would significantly alter the company's fundamental outlook or warrant a change in investment recommendation. It primarily confirms ongoing alignment of management incentives with shareholder interests.

Keywords

Balchem, BCPC, Insider Trading, Form 4, Equity Compensation, Restricted Stock, Stock Options, Performance Stock Units, Executive Compensation